The European Medicines Regulator (EMA) has approved the fourth SARS-CoV-2 coronavirus vaccine for use in the European Union. It is a drug developed by Janssen-Cilag, a division of the American corporation Johnson & Johnson. Writes about it Reuters.
It is reported that for the successful use of this vaccine, not two doses, as with competitors, are sufficient, but one. It is believed that this will help speed up the vaccination of Europeans.
The drug, like the products of Pfizer, AstraZeneca and Moderna, is recommended for patients over 18 years of age.
Also, this vaccine was approved in Canada and Bahrain, trials are underway in South Africa. In the United States, vaccination with the company's drug was also made possible, but the country's chief infectious disease specialist, Anthony Fauci, expressed doubts that vaccination with one dose is as effective as two: according to him, switching to such a drug could cause mistrust in people and slow down the vaccination process.
